Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Immunol ; 181(11): 7843-52, 2008 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-19017974

RESUMO

Many human solid tumors express MHC class II (MHC-II) molecules, and proteins normally localized to melanosomes give rise to MHC-II-restricted epitopes in melanoma. However, the pathways by which this response occurs have not been defined. We analyzed the processing of one such epitope, gp100(44-59), derived from gp100/Pmel17. In melanomas that have down-regulated components of the melanosomal pathway, but constitutively express HLA-DR*0401, the majority of gp100 is sorted to LAMP-1(high)/MHC-II(+) late endosomes. Using mutant gp100 molecules with altered intracellular trafficking, we demonstrate that endosomal localization is necessary for gp100(44-59) presentation. By depletion of the AP-2 adaptor protein using small interfering RNA, we demonstrate that gp100 protein internalized from the plasma membrane to such endosomes is a major source for gp100(44-59) epitope production. The gp100 trapped in early endosomes gives rise to epitopes that are indistinguishable from those produced in late endosomes but their production is less sensitive to inhibition of lysosomal proteases. In melanomas containing melanosomes, gp100 is underrepresented in late endosomes, and accumulates in stage II melanosomes devoid of MHC-II molecules. The gp100(44-59) presentation is dramatically reduced, and processing occurs entirely in early endosomes or stage I melanosomes. This occurrence suggests that melanosomes are inefficient Ag-processing compartments. Thus, melanoma de-differentiation may be accompanied by increased presentation of MHC-II restricted epitopes from gp100 and other melanosome-localized proteins, leading to enhanced immune recognition.


Assuntos
Apresentação de Antígeno/imunologia , Antígenos de Neoplasias/imunologia , Endossomos/imunologia , Epitopos de Linfócito T/imunologia , Antígenos HLA-DR/imunologia , Melanoma/imunologia , Melanossomas/imunologia , Glicoproteínas de Membrana/imunologia , Complexo 2 de Proteínas Adaptadoras/imunologia , Moléculas de Adesão Celular Neuronais/imunologia , Desdiferenciação Celular/imunologia , Linhagem Celular Tumoral , Proteínas Ligadas por GPI , Humanos , Transporte Proteico/imunologia , RNA Interferente Pequeno/imunologia , Antígeno gp100 de Melanoma
2.
J Immunol ; 177(8): 5440-50, 2006 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-17015730

RESUMO

Although multiple components of the class I MHC processing pathway have been elucidated, the participation of nonproteasomal cytosolic enzymes has been largely unexplored. In this study, we provide evidence for multiple cytosolic mechanisms in the generation of an HLA-A*0201-associated epitope from tyrosinase. This epitope is presented in two isoforms containing either Asn or Asp, depending on the structure of the tyrosinase precursor. We show that deamidation of Asn to Asp is dependent on glycosylation in the endoplasmic reticulum (ER), and subsequent deglycosylation by peptide-N-glycanase in the cytosol. Epitope precursors with N-terminal extensions undergo a similar process. This is linked to an inability of ER aminopeptidase 1 to efficiently remove N-terminal residues, necessitating processing by nonproteasomal peptidases in the cytosol. Our work demonstrates that processing of this tyrosinase epitope involves recycling between the ER and cytosol, and an obligatory interplay between enzymes involved in proteolysis and glycosylation/deglycosylation located in both compartments.


Assuntos
Aminopeptidases/metabolismo , Apresentação de Antígeno , Citosol/enzimologia , Retículo Endoplasmático/metabolismo , Epitopos/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Monofenol Mono-Oxigenase/imunologia , Peptídeo Hidrolases/metabolismo , Peptídeo-N4-(N-acetil-beta-glucosaminil) Asparagina Amidase/metabolismo , Retículo Endoplasmático/enzimologia , Glicosilação , Antígenos HLA-A/imunologia , Antígeno HLA-A2 , Humanos , Antígenos de Histocompatibilidade Menor
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA